NCT02111122View on ClinicalTrials.gov

Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2016

Study Completion Date

August 31, 2016

Conditions
Sleep-wake Disturbances in Motor-phase Parkinson's Disease
Interventions
DRUG

Sodium Oxybate

DRUG

Placebo

Trial Locations (1)

8006

Department of Neurology, Zurich

All Listed Sponsors
lead

Christian Baumann

OTHER

NCT02111122 - Study of the Symptomatic Effects of Nocturnal Sodium Oxybate in Parkinson's Disease | Biotech Hunter | Biotech Hunter